Skip to main content
PMC home page
Cancer Science logoLink to Cancer Science
. 2005 Aug 19;95(12):969–976. doi: 10.1111/j.1349-7006.2004.tb03185.x

Skp2 overexpression is a p27Kip1‐independent predictor of poor prognosis in patients with biliary tract cancers

Takahiro Sanada 1,2, Sana Yokoi 1,4, Shigeki Arii 2, Kohichiroh Yasui 1,4, Issei Imoto 1,4, Johji Inazawa 1,3,4,✉
PMCID: PMC11158159  PMID: 15596046

Abstract

To better understand the pathogenesis of biliary tract carcinoma (ETC) and to increase the accuracy of predicting outcomes for patients with this disease, we performed molecular cytogenetic analyses of BTC cell lines and tumors to identify non‐random amplification(s) and target gene(s) within the amplicons. Among several non random chromosomal aberrations detected in BTC cell lines by comparative genomic hybridization, gain/amplification of DNA at 5p was the most frequently observed alteration. We assessed the copy number and expression status of the possible target gene SKP2 for 5p amplification in cell lines and 33 primary stage II or III tumors of BTC. SKP2 was amplified, and subsequently overexpressed in both cell lines and primary tumors of BTC. However, levels of Skp2 and p27Kip1 proteins were not correlated inversely. Heightened expression of Skp2 and reduced expression of p27Kip1 were both associated with a shorter disease‐free and/or overall survival in univariate analyses. In multivariate regression analyses, Skp2 and p27Kip1 were independent predictive factors. Those results suggest that (a) overexpression of Skp2 through an amplification mechanism may contribute to the progression of BTC, (b) not only each molecule, but also the combination of Skp2 and p27Kip1, might be a useful predictor of the prognosis of BTC, and (c) molecular targets of Skp2 other than p27Kip1 may also be important factors in the pathogenesis of this disease.

References

  • 1. Japanese Society of Biliary Surgery. Classification of biliary tract carcinoma. 1st ed. Tokyo : Kanehara; 2001. [Google Scholar]
  • 2. Lotze MT, Flickinger JC, Carr BI. Hepatobiliary neoplasms. In: DeVita VT, Hellman S, Rosenberg SA., editors. Cancer: Principles and oncology. 4th ed. Philadelphia , PA : J. B. Lippincott; 1993. p. 883–914. [Google Scholar]
  • 3. Henson DE, Albores SJ, Corle D. Carcinoma of the extrahepatic bile ducts. Histologic types, stage of disease, grade, and survival rates. Cancer (Phila.) 1992; 70: 1498–501. [DOI] [PubMed] [Google Scholar]
  • 4. Henson DE, Albores SJ, Corle D. Carcinoma of the gallbladder. Histologic types, stage of disease, grade, and survival rates. Cancer (Phila.) 1992; 70: 1493–7. [DOI] [PubMed] [Google Scholar]
  • 5. Vogelstein B, Kinzler KW. The multistep nature of cancer. Trends Genet 1993; 9: 138–41. [DOI] [PubMed] [Google Scholar]
  • 6. Kallioniemi A, Kallioniemi OP, Sudar D, Rutovitz D, Gray JW, Waldman F, Pinkel D. Comparative genomic hybridization for molecular cytogenetic analysis of solid tumors. Science (Wash. DC) 1992; 258: 818–21. [DOI] [PubMed] [Google Scholar]
  • 7. Fukuda Y, Kurihara N, Imoto I, Yasui K, Yoshida M, Yanagihara K, Park JG, Nakamura Y, Inazawa J. CD44 is a potential target of amplification within the 11pl3 amplicon detected in gastric cancer cell lines. Genes Chromosom Cancer 2000; 29: 315–24. [DOI] [PubMed] [Google Scholar]
  • 8. Yokoi S, Yasui K, Saito‐Ohara F, Koshikawa K, Iizasa T, Fujisawa T, Terasaki T, Horii A, Takahashi T, Hirohashi S, Inazawa J. A novel target gene, SKP2, within the 5pl3 amplicon that is frequently detected in small cell lung cancers. Am. J Pathol 2002; 161: 207–16. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 9. Saito‐Ohara F, Imoto I, Inoue J, Hosoi H, Nakagawara A, Sugimoto T, Inazawa J. PPM1D is a potential target for 17q gain in neuroblastoma. Cancer Res 2003; 63: 1876–83. [PubMed] [Google Scholar]
  • 10. Ariyama Y, Sakabe T, Shinomiya T, Mori T, Fukuda Y, Inazawa J. Identification of amplified DNA sequences on double minute chromosomes in a leukemic cell line KY821 by means of spectral karyotyping and comparative genomic hybridization. J Hum. Genet 1998; 43: 187–90. [DOI] [PubMed] [Google Scholar]
  • 11. Yasui K, Arii S, Zhao C, Imoto I, Ueda M, Nagai H, Emi M, Inazawa J. TFDP1, CUL4A, and CDC16 identified as targets for amplification at 13q34 in hepatocellular carcinomas. Hepatology 2002, 35: 1476–84. [DOI] [PubMed] [Google Scholar]
  • 12. Imoto I, Tsuda H, Hirasawa A, Miura M, Sakamoto M, Hirohashi S, Inazawa J. Expression of cIAP1, a target for 11q22 amplification, correlates with resistance of cervical cancers to radiotherapy. Cancer Res 2002; 62: 4860–6. [PubMed] [Google Scholar]
  • 13. Gstaiger M, Jordan R, Lim M, Catzavelos C, Mestan J, Slingerland J, Krek W. Skp2 is oncogenic and overexpressed in human cancers. Proc Natl Acad Sci USA 2001; 98: 5043–8. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 14. Kudo Y, Kitajima S, Sato S, Miyauchi M, Ogawa I, Takata T. High expression of S‐phase kinase‐interacting protein 2, human F‐box protein, correlates with poor prognosis in oral squamous cell carcinomas. Cancer Res 2001; 61: 7044–7. [PubMed] [Google Scholar]
  • 15. Masuda TA, Inoue H, Sonoda H, Mine S, Yoshikawa Y, Nakayama K, Nakayama K, Mori M. Clinical and biological significance of S‐phase kinase‐associated protein 2 (Skp2) gene expression in gastric carcinoma: modulation of malignant phenotype by Skp2 overexpression, possibly via p27 proteolysis. Cancer Res 2002; 62: 3819–25. [PubMed] [Google Scholar]
  • 16. Chiarle R, Fan Y, Piva R, Boggino H, Skolnik J, Novero D, Palestro G, de Wolf‐Peeters C, Chilosi M, Pagano M, Inghirami G. S‐phase kinase‐associated protein 2 expression in non‐Hodgkin's lymphoma inversely correlates with p27 expression and defines cells in S phase. Am J Pathol 2002; 160: 1457–66. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 17. Shiraishi K, Kusano N, Okita S, Oga A, Okita K, Sasaki K. Genetic aberrations detected by comparative genomic hybridization in biliary tract cancers. Oncology 1999; 57: 42–9. [DOI] [PubMed] [Google Scholar]
  • 18. Dowen SE, Neutze DM, Pett MR, Cottage A, Stern P, Coleman N, Stanley MA. Amplification of chromosome 5p correlates with increased expression of Skp2 in HPV‐immortalized keratinocytes. Oncogene 2003; 22: 2531–40. [DOI] [PubMed] [Google Scholar]
  • 19. Hui AM, Cui X, Makuuchi M, Li X, Shi YZ, Takayama T. Decreased p27Kip1 expression and cyclin Dl overexpression, alone and in combination, influence recurrence and survival of patients with resectable extrahepatic bile duct carcinoma. Hepatology 1999; 30: 1167–73. [DOI] [PubMed] [Google Scholar]
  • 20. Hui AM, Li X, Shi YZ, Torzilli G, Takayama T, Makuuchi M. p27KiP1 expression in normal epithelia, precancerous lesions, and carcinomas of the gallbladder: association with cancer progression and prognosis. Hepatology 2000; 31: 1068–72. [DOI] [PubMed] [Google Scholar]
  • 21. Penin RM, Fernandez‐Figueras MT, Puig L, Rex J, Ferrandiz C, Ariza A. Over‐expression of p45SKP2 in Kaposi's sarcoma correlates with higher tumor stage and extracutaneous involvement but is not directly related to p27KIP1 down‐regulation. Mod Pathol 2002; 15: 1227–35. [DOI] [PubMed] [Google Scholar]
  • 22. Oliveira AM, Okuno SH, Nascimento AG, Lloyd RV. Skp2 protein expression in soft tissue sarcomas. J Clin Oncol 2003; 21: 722–7. [DOI] [PubMed] [Google Scholar]
  • 23. Dowen SE, Scott A, Mukherjee G, Stanley MA. Overexpression of Skp2 in carcinoma of the cervix does not correlate inversely with p27 expression. Int J Cancer 2003; 105: 326–30. [DOI] [PubMed] [Google Scholar]
  • 24. Bhattacharya S, Garriga J, Calbo J, Yong T, Haines DS, Grana X. SKP2 associates with p130 and accelerates p130 ubiquitylation and degradation in human cells. Oncogene 2003; 22: 2443–51. [DOI] [PubMed] [Google Scholar]
  • 25. Bornstein G, Bloom J, Sitry‐Shevah D, Nakayama K, Pagano M, Hershko A. Role of the SCFSkp2 ubiquitin ligase in the degradation of p21Cip1 in S phase. J Biol Chem. 2003; 278: 25752–7. [DOI] [PubMed] [Google Scholar]
  • 26. von der Lehr N, Johansson S, Wu S, Bahrain F, Castell A, Cetinkaya C, Hydbring P, Weidung I, Nakayama K, Nakayama KI, Soderberg O, Kerppola TK, Larsson LG. The F‐box protein Skp2 participates in c‐Myc proteosomal degradation and acts as a cofactor for c‐Myc‐regulated transcription. Mol Cell 2003; 11: 1189–200. [DOI] [PubMed] [Google Scholar]
  • 27. Kim SY, Herbst A, Tworkowski KA, Salghetti SE, Tansey WP. Skp2 regulates myc protein stability and activity. Mol Cell 2003; 11: 1177–88. [DOI] [PubMed] [Google Scholar]
  • 28. Kamura T, Kara T, Kotoshiba S, Yada M, Ishida N, Imaki H, Hatakeyama S, Nakayama K, Nakayama KI. Degradation of p57Kip2 mediated by SCFSkp2‐dependent ubiquitylation. Proc Natl Acad Sci USA 2003; 100: 10231–6. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 29. Shirane M, Harumiya Y, Ishida N, Hirai A, Miyamoto C, Hatakeyama S, Nakayama K, Kitagawa M. Down‐regulation of p27KIPl by two mechanisms, ubiquitin‐mediated degradation and proteolytic processing. J Biol Chem 1999; 274: 13886–93. [DOI] [PubMed] [Google Scholar]
  • 30. Malek NP, Sundberg H, McGrew S, Nakayama K, Kyriakides TR, Roberts JM, Kyriakidis TR. A mouse knock‐in model exposes sequential proteolytic pathways that regulate p27Kipl in Gl and S phase. Nature 2001; 413: 323–7. [DOI] [PubMed] [Google Scholar]
  • 31. Hara T, Kamura T, Nakayama K, Oshikawa K, Hatakeyama S, Nakayama K. Degradation of p27Kipl at the G(0)‐G(1) transition mediated by a Skp2‐independent ubiquitination pathway. J Biol Chem. 2001; 276: 48937–43. [DOI] [PubMed] [Google Scholar]
  • 32. Rodier G, Montagnoli A, Di Marcotullio L, Coulombe P, Draetta GF, Pagano M, Meloche S. p27 cytoplasmic localization is regulated by phosphorylation on Ser 10 and is not a prerequisite for its proteolysis. EMBO J 2001; 20: 6672–82. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 33. Wirbelauer C, Sutterluty H, Blondel M, Gstaiger M, Peter M, Reymond F, Krek W. The F‐box protein Skp2 is a ubiquitylation target of a Cul 1‐based core ubiquitin ligase complex: evidence for a role of Cul 1 in the suppression of Skp2 expression in quiescent fibroblasts. EMBO J 2000; 19: 5362–75. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 34. Imaki H, Nakayama K, Delehouzee S, Handa H, Kitagawa M, Kamura T, Nakayama KI. Cell cycle‐dependent regulation of the Skp2 promoter by GA‐binding protein. Cancer Res 2003; 63: 4607–13. [PubMed] [Google Scholar]
  • 35. Shigemasa K, Gu L, O'Brien TJ, Ohama K. Skp2 overexpression is a prognostic factor in patients with ovarian adenocarcinoma. Clin Cancer Res 2003; 9: 1756–63. [PubMed] [Google Scholar]
  • 36. Yokoi S, Yasui K, Iizasa T, Takahashi T, Fujisawa T, Inazawa J. Down‐regulation of SKP2 induces apoptosis in lung‐cancer cells. Cancer Sci 2003; 94: 344–9. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 37. Mitchell BS. The proteasome‐an emerging therapeutic target in cancer. N Engl J Med 2003; 348: 2597–8. [DOI] [PubMed] [Google Scholar]

Articles from Cancer Science are provided here courtesy of Wiley

RESOURCES